There are currently 1544 clinical trials in Baltimore, Maryland looking for participants to engage in research studies. Trials are conducted at various facilities, including Johns Hopkins University, Johns Hopkins Hospital, University of Maryland and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
FRIEND: Fibroids and Unexplained Infertility Treatment with Epigallocatechin Gallate; a Natural CompounD in Green Tea
NCT05364008
Recruiting
The objective of this study is to determine the effect of low caffeine green tea extract containing 45% epigallocatechin gallate (EGCG) on fibroids and subsequent pregnancy and live births in women seeking fertility treatment. The population will consist of 50 women desirous of conceiving, ages ≥18 to ≤40 years (at time of consent), and known to have class 2-6 fibroids, according to the FIGO staging system.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
03/04/2025
Locations: Johns Hopkins, Division of Reproductive Science and Women's Health Research, Baltimore, Maryland
Conditions: Leiomyoma, Uterine
Register for Updates
Phase 1 Study of Intratumoral Administration of VAX014 in Subjects with Advanced Solid Tumors
NCT05901285
Recruiting
The purpose of this research study is to evaluate the safety, tolerability and activity of VAX014 for intratumoral injections (VAX014) in patients with advanced solid tumors. VAX014 is a targeted oncolytic agent designed to kill tumor cells following intratumoral injection into advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: University of Maryland, Baltimore, Maryland
Conditions: Advanced Solid Tumor
Register for Updates
Study of LP-184 in Patients with Advanced Solid Tumors
NCT05933265
Recruiting
The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Participants will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patie... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: John Hopkins - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation
Register for Updates
Confocal Laser Endomicroscopy As an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
NCT03492151
Recruiting
The study schema is shown in Figure 4. (A) All patients referred to one of the participating academic centers for EUS evaluation of the PCL will be enrolled in the protocol if they satisfy inclusion criteria. Patient consent will be obtained during the clinic visit or prior to their EUS. EUS-guided nCLE imaging is first performed (B) followed by EUS-guided FNA and aspiration of cyst fluid. The cyst fluid is analyzed for CEA and cytology. As per institutional standard of care, the cyst fluid is a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: The Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Pancreatic Cyst
Register for Updates
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
NCT06267391
Recruiting
This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
03/03/2025
Locations: John Hopkins, Baltimore, Maryland
Conditions: Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes
Register for Updates
A Multi-Level Trauma-Informed Approach to Increase HIV Pre-exposure Prophylaxis Initiation Among Black Women
NCT06703060
Recruiting
U.S. epidemiological data indicates that Black women are a high-risk HIV disparity group, yet initiation of novel prevention strategies like pre-exposure prophylaxis (PrEP) among this group is stagnant. Socio-structural challenges like intimate partner violence and gendered racism can constrain PrEP access among Black women, but few implementation studies have mitigated these challenges to improve PrEP initiation. The proposed research aims to implement and assess the effectiveness, implementati... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
Conditions: HIV Prevention, PrEP, Women, Intimate Partner Violence (IPV)
Register for Updates
Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)
NCT05120284
Recruiting
Conduct a multicenter, open label Phase IIA trial of oral DCA in 40 surgical patients with recurrent GBM who have clinically indicated debulking surgery planned. No patients will be recruited at UF. Patients will be genotyped to establish safe dosing regimens and will be randomized to receive DCA (N=20) or no DCA (N=20) for one week prior to surgery. Deidentified blood and tumor tissue obtained at surgery will be assessed at UF for biochemical markers of DCA dynamics.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/03/2025
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Glioblastoma Multiforme
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05259839
Recruiting
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: University of Maryland, Baltimore /ID# 243679, Baltimore, Maryland
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618
Recruiting
The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.
Gender:
ALL
Ages:
Between 12 years and 60 years
Trial Updated:
03/01/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: C3G
Register for Updates
Comparing Efficacy & Safety of TNX-1300 to Placebo with UC for Treatment of Acute Cocaine Intoxication in ED Subjects (CATALYST)
NCT06045793
Recruiting
This is a Phase 2 single-blind, randomized, multicenter study to compare the efficacy and safety of a single dose of TNX-1300 to placebo with usual care in patients with acute cocaine intoxication within the emergency department setting.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
02/28/2025
Locations: University Of Maryland Medical Center, Baltimore, Maryland
Conditions: Cocaine Use, Cocaine Intoxication, Cocaine Toxicity, Cocaine Abuse, Cocaine Adverse Reaction
Register for Updates
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: GSK Investigational Site, Baltimore, Maryland
Conditions: Neoplasms
Register for Updates
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
NCT06616597
Recruiting
To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Prostate Cancer (Adenocarcinoma), Metastatic Prostate Cancer
Register for Updates